Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

A new study finds that a common blood test for ovarian cancer may miss some Black and Native American patients, delaying ...

The University of Pennsylvania has taken a novel approach to ensure that women with suspicious adnexal lesions are referred ...

today announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC in an oral presentation at the Society of Gynecologic Oncology (SGO) 2025 ...

Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor afuresertib failed to improve progression-free survival (PFS) when added to ...

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced ...

Clinicians should adopt a risk-based, rather than biopsy-first, approach to encourage biopsy acceptance and improve early ...

Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment ...

In patients with a negative sentinel lymph node biopsy, omitting pelvic lymphadenectomy does not compromise disease-free ...

The cancer antigen (CA)-125 test may miss ovarian cancer in some Black and Native American patients, delaying their treatment ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to ...